AlphAIAlphAI — Financial news for AI agents
rttnews.com$CTY

City Therapeutics Prices Upsized $200 Mln IPO At $18/shr

City Therapeutics (CTY) priced its upsized IPO at $18 per share, raising $200M from 11M shares. Underwriters have a 30-day option for additional shares. Trading starts Oct 16, 2026, on Nasdaq. The company focuses on RNAi therapeutics for diseases like thromboembolic conditions and retinal diseases.

Original reporting
rttnews.com
Published Oct 16, 2026, 3:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 3:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefIPO
Primary signal
$CTY
Bullish
high confidence
Mentioned
$CTY
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CTYBullishHigh
01

Why it matters

The $200 million capital raise provides runway for its pipeline and signals market confidence.

02

Market read

First report of City Therapeutics' IPO pricing; creates immediate trading interest for the debut.

03

What to watch

Potential regulatory hurdles for RNAi therapies could temper enthusiasm despite strong raise.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

City Therapeutics is a clinical‑stage RNAi biotech preparing its Nasdaq debut.

Company-level read

Ticker impact

$CTYBullishHigh confidence
Context

City Therapeutics priced an upsized $200 million IPO at $18 per share, set to debut on Nasdaq.

Expected impact

potential upward pressure as the stock opens, driven by fresh capital inflow and market interest

Evidence & confidence

New primary disclosure of a sizable biotech raise; first report of pricing creates immediate trading opportunity.

Market effects

Sector

Adds to biotech IPO pipeline, may boost sector sentiment and peer valuations.

Regional

U.S. biotech market sees fresh capital, could attract further investor allocations.

Global

Limited to U.S. markets; modest global effect beyond biotech investors.

Counterpoint

What could challenge this read

If the IPO is oversubscribed, pricing may be too aggressive, leading to a post‑launch sell‑off.

Key entities

  • underwriter
    Goldman Sachs & Co. LLC

    Joint book‑running manager for the IPO.

  • underwriter
    Jefferies

    Joint book‑running manager for the IPO.

  • underwriter
    Stifel

    Joint book‑running manager for the IPO.

Read at source← All news

StoryCity Therapeutics upsizes IPO, sells 11.1 M shares at $18 each, raising $200 M

Also covered by

5 outlets

Related articles

$CTYLowAI 8/10

City Therapeutics Doses First Participant in CITY-RBP4 Phase 1 Trial

City Therapeutics dosed the first participant in its Phase 1 trial of CITY-RBP4, a treatment for Stargardt disease. The trial will assess safety and efficacy, with initial data expected in mid-2027. CITY-RBP4 aims to slow retinal damage by reducing vitamin A delivery to the eye. This is the company's second program in clinical development.

tradingview.com
$CTYLowAI 8/10

City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease

CITY THERAPEUTICS, INC. (CTY) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in S

SEC EDGAR 8-K
$CTYHigh

Jefferies initiates City Therapeutics stock with buy rating

Jefferies initiated City Therapeutics (NASDAQ:CTY) with a buy rating and $32 price target, citing its RNAi platform and lead programs. The stock, trading at $18.67, has declined 16.7% over six months. Jefferies highlighted potential catalysts and strong cash position. The company's IPO saw high demand, with limited share allocation due to oversubscription.

investing.com
$CTYHighAI 9/10

City Therapeutics raises $230M in upsized Nasdaq IPO

City Therapeutics (CTY) raised $230M in its Nasdaq IPO, selling 12.8M shares at $18 each, including underwriters' option. The biotech firm focuses on RNA interference therapeutics. Shares began trading on Oct. 16, 2026. Joint book-runners include Goldman Sachs, Jefferies, Stifel, and Oppenheimer.

investing.com